NDA 050823/S-009

SUPPLEMENT APPROVAL

B. Braun Medical, Inc.
Attention: Cindy Katsempris
Director, Regulatory Affairs
901 Marcon Boulevard
Allentown, PA 18109-9341

Dear Ms. Katsempris:

Please to refer to your supplemental new drug application (sNDA) dated July 27, 2020, received July 31, 2020, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Ceftazidime for Injection USP and Dextrose Injection USP in the Duplex Container, 1g and 2g.

This Prior Approval sNDA provides for revisions to the prescribing information (PI) to comply with the requirements of the Pregnancy and Lactation Labeling Rule (PLLR).

More specifically, revisions have been made to the **HIGHLIGHTS OF PERSCRIBING INFORMATION, INDICATIONS AND USAGE (1.0)** section, **WARNINGS AND PRECAUTIONS (5.0) Neurological Adverse Reactions (5.4)** and **Risk of Development of Drug-resistant Bacteria (5.6)** subsections, **DRUG INTERACTIONS (7.0)** section, **Drug/Laboratory Test Interactions (7.3)** subsection, **USE IN SPECIFIC POPULATIONS (8.0)** section, **Pregnancy (8.1), Lactation (8.2), Females and Males of Reproductive Potential (8.3)** and **Pediatric Use (8.4)** subsections, **DESCRIPTION (11)** section, and the **NON-CLINICAL TOXICILOGY (13.0)** section, **Carcinogenesis, Mutagenesis and Impairment of Fertility (13.1)** subsection.

In addition, minor editorial revisions have been made throughout the PI for standardization and consistency and the product container labels have been updated to provide information as it relates to storage instructions prior to reconstitution.

APPROVAL & LABELING

We have completed our review of this application, as amended and it is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.[1] Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CONTAINER LABELING

Submit final printed container labels that are identical to the enclosed container labels submitted on July 23, 2021, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission "**Final Printed Labeling for approved NDA 50-823/S-009**." Approval of this submission by FDA is not required before the labeling is used.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

---

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

If you have any questions, call J. Christopher Davi, MS, Senior Regulatory Project Manager, at (301) 796-0702.

Sincerely,

{See appended electronic signature page}

Dmitri Iarikov, MD, PhD
Deputy Director
Division of Anti-Infectives
Office of Infectious Diseases
Center for Drug Evaluation and Research

ENCLOSURES: Prescribing Information
Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DMITRI IARIKOV
10/20/2021 09:54:32 AM